Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00188266
Status:
COMPLETED
Last Update Posted:
2017-09-20
First Post:
2005-09-09
Brief Title:
Study of Adjuvant Radiochemotherapy for Gastric Cancer
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Prospective Phase III Study of Adjuvant Radiochemotherapy for Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In 1991 the South West Oncology Group SWOG conducted a randomized study of adjuvant chemotherapy 5-fluorouracil and folinic acid with concurrent radiation 4500 cGy25 fractions versus surgery alone for patients with completely resected gastric carcinoma
This landmark study showed the benefit of adjuvant treatment for gastric cancer and radically changed the treatment of this disease However the resulting standard treatment has severe acute toxicity and despite this advance 50 of patients still die of gastric cancer The investigators hope to develop a modified protocol using active chemotherapy agents but with reduced acute toxicity Such an approach could ultimately be studied against the current SWOG approach to determine whether or not the addition of cisplatinum improves efficacy
Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil 5FUthrough an intravenous catheter continuously over 12 weeks Patients will not be admitted to hospital to receive the chemotherapy but will need to wear a waist pack to carry a small pump that will deliver the medication They will however need to make regular visits to have their medication bags changed Patients will also receive Cisplatin intravenously every 2 weeks for 4 doses In addition patients will also receive radiation to their stomach lymph nodes and the area where they had their surgery This study also comprise of a questionnaire for us to see how patients cancer and treatment is affecting their quality of life Patients will have regular follow-up by their physicians
This landmark study showed the benefit of adjuvant treatment for gastric cancer and radically changed the treatment of this disease However the resulting standard treatment has severe acute toxicity and despite this advance 50 of patients still die of gastric cancer The investigators hope to develop a modified protocol using active chemotherapy agents but with reduced acute toxicity Such an approach could ultimately be studied against the current SWOG approach to determine whether or not the addition of cisplatinum improves efficacy
Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil 5FUthrough an intravenous catheter continuously over 12 weeks Patients will not be admitted to hospital to receive the chemotherapy but will need to wear a waist pack to carry a small pump that will deliver the medication They will however need to make regular visits to have their medication bags changed Patients will also receive Cisplatin intravenously every 2 weeks for 4 doses In addition patients will also receive radiation to their stomach lymph nodes and the area where they had their surgery This study also comprise of a questionnaire for us to see how patients cancer and treatment is affecting their quality of life Patients will have regular follow-up by their physicians
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None